Matrix-M
- Generic Name
- Matrix-M
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- YZ7P8Y8ECX
- Background
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
- Associated Conditions
- -
- Associated Therapies
- -
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
Phase 1
Active, not recruiting
- Conditions
- Epstein-Barr Virus InfectionInfectious MononucleosisHerpesvirus
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 1000
- Registration Number
- NCT05683834
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath